CG Oncology Revenue and Competitors
Estimated Revenue & Valuation
- CG Oncology's estimated annual revenue is currently $12.7M per year.
- CG Oncology's estimated revenue per employee is $155,000
Employee Data
- CG Oncology has 82 Employees.
- CG Oncology grew their employee count by 34% last year.
CG Oncology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Executive Assistant to CEO & Chief Medical Officer | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | President & Chief Operating Officer | Reveal Email/Phone |
4 | VP Regulatory Affairs | Reveal Email/Phone |
5 | VP, Supply Chain and Logistics | Reveal Email/Phone |
6 | VP, Enterprise Project and Alliance Management | Reveal Email/Phone |
7 | VP Clinical Operations | Reveal Email/Phone |
8 | VP - Finance, Accounting & Administration | Reveal Email/Phone |
9 | Senior Director Analytical Development and Quality Control | Reveal Email/Phone |
10 | Sr. Director & Head Human Resources | Reveal Email/Phone |
CG Oncology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is CG Oncology?
CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer. Our lead candidate, CG0070, is a selective oncolytic immunotherapy in multiple clinical programs, including ongoing trials with CG0070 as a monotherapy in a global Phase 3 study (BOND3) for the treatment of BCG-unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC), and also in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 study (CORE1) in the same indication. Additional indications in muscle-invasive bladder cancer (MIBC) and other solid tumors are being pursued with CG0070 in combination with immune checkpoint modulators. At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.
keywords:N/A
N/A
Total Funding
82
Number of Employees
$12.7M
Revenue (est)
34%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CG Oncology News
California-based CG Oncology, a clinical-stage pharmaceutical company that primarily develops immunotherapies for cancer, presented positive...
CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer...
Presented in part at the European Society for Medical Oncology Virtual ... Propella Therapeutics, Genzyme, Sanofi, Sesen Bio, CG Oncology,...
Other Companies in Irvine
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.6M | 82 | 9% | N/A |
#2 | $11.9M | 82 | 4% | N/A |
#3 | $18.7M | 82 | 1% | N/A |
#4 | $3.5M | 82 | 34% | N/A |
#5 | $16.7M | 82 | 30% | N/A |